Research Areas

——

 

Sinogen focuses on the research and development of a series of tumor-targeting oncolytic bacteria and oncolytic virus drugs based on metabolic abnormalities in tumor cells.
After years of development, Sinogen has become a multi-functional biomedical enterprise covering pharmacological research, drug screening, pilot plant scale-up production, clinical research, and registration application, and has developed an efficient independent innovation system for product development and achievement transformation.

Product Characteristics

 

Business Development

——

 

Collaborations

——

 

 

Sinogen Pharmaceutical is committed to the development of innovative biological anti-tumor drugs to meet the global market demand for treating malignant tumors. Our products have global intellectual property protection and commercialization rights. We are looking forward to find partners worldwide to jointly promote the development and application of revolutionary new anti-tumor drugs.

 

 

 

 

Contact: BD@sinogen.cc

Current Partnerships

——

Technical Platform of Innovative Oncolytic Drugs Targeting Tumor Metabolism

 

Based on the characteristics of abnormal tumor metabolism, the platform adopts the existing bacterial delivery system to carry and encode active target molecules consuming tumor cell-dependent nutrients to precisely target the tumor and consume tumor cell-dependent nutrients. The platform is capable of basic research on tumor metabolism, as well as designing, screening and optimization of target genes, screening and construction of plasmid vectors, target protein expression and activity identification, and construction of tumor-targeted oncolytic bacteria drugs.

[1]Front. Cell Dev. Biol., 12 January 2021 | https://doi.org/10.3389/fcell.2020.603837
[2]Trends Endocrinol Metab. 2021 Jun;32(6):367-381.

The company was established in Guangzhou as a R&D biopharmaceutical company in July 2016

 

We have built a research system from lab scale to pilot scale, including low-temperature cold storage room, pilot plant, QC testing room, R&D laboratory, etc. The platform is intended for the development of original genetic engineering drugs, upstream and downstream research and development of products, and the development of core technologies for pilot- and large-scale production. In addition to carrying out research and development of our own varieties, the platform can also undertake external business such as genetic engineering drug technology development and process research, process validation, and quality control, and stability development techniques of biological products.


[1]Salmonella typhimurium lacking ribose chemoreceptors localize in tumor quiescence and induce apoptosis[J]. Cancer Research, 2007, 67(7):3201-3209.
[2] Biopharmaceutical Drug Development Pillars: Begin With the End in Mind .Clin Pharmacol Ther. 2019 Jan;105(1):33-35.

Technical Platform for Research on Tumor-targeting Mechanism of Oncolytic Bacteria

 

Bacterial therapy for tumor is one of the most concerned antitumor therapies at present. It is extremely important to investigate and determine the tumor-targeting mechanism of oncolytic bacteria for tumor treatment. We have constructed a technical platform for research on tumor-targeting mechanism of oncolytic bacteria in terms of tumor immunity, tumor vascular distribution, and bacterial chemotaxis mechanism, and in combination with flow cytometry, genome sequencing, protein immunoblotting, ELISA, bioinformatics analysis, and other technologies. With the help of this platform, the tumor-targeting and -colonization mechanism of oncolytic bacteria will be further investigated, providing a theoretical basis for the research and development of safe, effective, and highly targeted oncolytic bacteria.

 

[1] Ze Mi, Zhi-Chao Feng, et al. Salmonella-Mediated Cancer Therapy: An Innovative Therapeutic Strategy[J].Journal Of Cancer, 2019; 10(20): 4765–4776.
[2]Shibin, Zhou, Claudia, et al. Tumour-targeting bacteria engineered to fight cancer[J]. Nature reviews. Cancer, 2018.

Technical Platform for In Vitro and In Vivo Pharmacodynamic Evaluation of Antitumor Drugs

 

We have established a technical platform for preclinical pharmacodynamic evaluation of antitumor drugs at different levels of molecules, cells, and animals. The platform is designed to evaluate tumor angiogenesis, tumor metastasis, tumor immunity, cell cycle arrest, tumor drug resistance, tumor cell apoptosis, etc. in each link of tumorigenesis, proliferation, growth, and metastasis. By combining in vivo imaging technology and applied genomics with proteomics technology, we have established experimental models based on novel pharmacodynamics and human disease pathogenesis, including the establishment of a tumor cell bank and various tumor-bearing animal models, e.g., nude mouse model for human hepatocellular carcinoma cell line HCCLM3, nude mouse model for human small cell lung cancer cell line A549, nude mouse model for human small cell lines H446 and H69, nude mouse model for human cervical cancer cell line Hela, nude mouse model for human breast cancer cell line MDA-MB-231, nude mouse model for human glioblastoma in situ cell line U87, nude mouse model for human pancreatic cancer cell line CFPAC-1, mouse model for lymphocytic leukemia cell line L1210, mouse model for primary acute leukemia, mouse model for Lewis lung cancer, B16 melanoma model, mouse 4T1 breast cancer model, mouse model for PyMT-induced breast cancer in situ, patient-derived organoid (PDO) model, and human-derived tumor xenograft (PDX) model, and mastered the techniques of new targets and pharmacodynamic evaluation for the research and development of innovative drugs.

Publication of Paper

——

 

● The dual anticancer mechanism of metabolism and immunity
Broad spectrum solid tumor treatment capability, unlimited oncogene phenotype
Actively targeting tumors and controlling their distant metastasis

Multiple administration pathways including intravenous, intratumoral, and interventional therapy. Rapid and powerful tumor lysis

Independent technology and production capacity guarantee

More than 50 invention patents worldwide

Mechanism

 

Cell Reports Medicine 

 

Targeted deprivation of methionine with engineeredSalmonella leads to oncolysis and suppression ofmetastasis in broad types of animal tumor models

Sujin Zhou , Yan Lin , zhenggang Zhao , Yunhao Lai , Mengmeng Lu , Zishen Shao , Xinyu Mo , Yunping Mu ,Zhipeng Liang , Xinxing Wang , Jingming Qu , Hua Shen , Fanghong Li , and Allan Z Zhao 

2023/06/02

 

Learn More

Cancer Research on Prevention and Treatment

 

Therapeutic Effect of Recombinant Salmonella VNP20009-M on Osteosarcoma

ZHANG Xindan, ZHAO Zhenggang, ZHOU Sujin, MU Yunping, LI Meirong, LAI Yunhao, XIAO Gengmiao, LI Fanghong, ZHAO Zijian

2020/11/11

 

Learn More

Biomedicine& Pharmacotherapy

 

Inhibition of acute leukemia with attenuated Salmonella typhimurium strain VNP20009

Meirong Li, Mengmeng Lu, Yunhao Lai, Xindan Zhang, Yuyu Li, Ping Mao, Zhicheng Liang,Yunping Mu, Ying Lin, Allan Z. Zhao, Zhenggang Zhao,, Sujin Zhou,Fanghong Li

2020/06/20

 

Learn More

CANCER BIOLOGY & THERAPY

 

Suppression of pancreatic ductal adenocarcinoma growth by intratumoral deliveryof attenuated Salmonella typhimurium using a dual fluorescent live tracking system

Sujin Zhou, Zhenggang Zhao, Yan Lin, Sijia Gong, Fanghong Li, Jinshun Pan, Xiaoxi Li, Zhuo Gao,and Allan Z. Zhao

2016/04/18

 

Learn More

Cell Death & Disease

 

Deprivation of methionine inhibits osteosarcoma growth and metastasis via C1orf112-mediated regulation of mitochondrial functions

Xindan Zhang, Zhenggang Zhao, Xuepeng Wang, Shiwei Zhang, Zilong Zhao, Wenbin Feng, Lijun Xu, Junhua Nie, Hong Li,Jia Liu, Gengmiao Xiao, Yu Zhang, Haomiao Li, Ming Lu, Jialuo Mai, Sujin Zhou, Allan Z. Zhao  and Fanghong Li

2024/05/20

 

Learn More